How effective is Galantamine Hydrobromide for Short-term Memory Loss (Memory loss)? (a real world drug study)
Summary:
Overall ratings: 3/5 Long term ratings: 3.5/5
This is a phase IV clinical study of how effective Galantamine hydrobromide (galantamine hydrobromide) is for Short-term memory loss and for what kind of people. The study is created by eHealthMe from 4 Galantamine hydrobromide users and is updated continuously.
What is Galantamine hydrobromide?
Galantamine hydrobromide has active ingredients of galantamine hydrobromide. It is often used in dementia. eHealthMe is studying from 2,418 Galantamine hydrobromide users. Check the latest studies of Galantamine hydrobromide.
What is Short-term memory loss?
Short-term memory loss is found to be associated with 3,590 drugs and 4,535 conditions by eHealthMe. Check the latest studies of Short-term memory loss.
eHealthMe: drug outcomes in the real world
eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.
4 people are studied for taking Galantamine hydrobromide in Short-term memory loss
Overall effectiveness (number of people):
Long term (1+ years) effectiveness (number of people):
Galantamine hydrobromide effectiveness for Short-term memory loss (number of people):
Overall:
- not at all: 0
- somewhat: 1
- moderate: 2
- high: 1
- very high: 0
Long Term:
- not at all: 0
- somewhat: 0
- moderate: 1
- high: 1
- very high: 0
Gender of people who take Galantamine hydrobromide for Short-term memory loss *:
- female: 50 %
- male: 50 %
Age of people who take Galantamine hydrobromide for Short-term memory loss *:
- 0-1: 0.0 %
- 2-9: 0.0 %
- 10-19: 0.0 %
- 20-29: 0.0 %
- 30-39: 0.0 %
- 40-49: 0.0 %
- 50-59: 0.0 %
- 60+: 100 %
Who find Galantamine Hydrobromide more effective for Short-term Memory Loss?
Gender of people who take Galantamine hydrobromide for Short-term memory loss *:
- female: 0.0 %
- male: 100 %
Age of people who take Galantamine hydrobromide for Short-term memory loss *:
- 0-1: 0.0 %
- 2-9: 0.0 %
- 10-19: 0.0 %
- 20-29: 0.0 %
- 30-39: 0.0 %
- 40-49: 0.0 %
- 50-59: 0.0 %
- 60+: 100 %
* Approximation only. Some reports may have incomplete information.
Do you take Galantamine hydrobromide?
- You can start a phase IV clinical trial to monitor Galantamine hydrobromide safety and effectiveness.How to use the study?
DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.
Related studies
Alternative drugs to, pros and cons of:
- Galantamine hydrobromide (2,418 reports)
Treatments, associated drugs and conditions:
- Short-term memory loss (244,445 reports)
How the study uses the data?
The study is based on galantamine hydrobromide (the active ingredients of Galantamine hydrobromide) and Galantamine hydrobromide (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study neither.
Who is eHealthMe?
With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Could Tacrolimus cause Methaemoglobinaemia? - now
- Could Tafinlar cause Joint Stiffness? - 5 seconds ago
- Could Simvastatin cause Eyelid Function Disorder? - 8 seconds ago
- Drug interactions of Granisetron Hydrochloride and Hydroxyzine - 9 seconds ago
- Could Diphen cause Tension Headache? - 9 seconds ago
- Cataplexy and Eczema - 13 seconds ago
- Cataplexy and Dermatitis - Atopic - 13 seconds ago
- Could Acetylsalicylic Acid cause Deformity? - 18 seconds ago
- Could Ramipril cause Visual Disturbance? - 19 seconds ago
- Could Metronidazole cause Linear Iga Disease? - 20 seconds ago